Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
100 项与 LAGE-1a阳性实体瘤 相关的临床结果
100 项与 LAGE-1a阳性实体瘤 相关的转化医学
0 项与 LAGE-1a阳性实体瘤 相关的专利(医药)